Cargando…

Acute myocarditis after COVID‐19 vaccination with mRNA‐1273 in a patient with former SARS‐CoV‐2 infection

We describe a case of a 20‐year‐old healthy man developing chest pain and classical symptoms of vaccine reactogenicity 12 h after receiving the first dose of mRNA‐1273 (Moderna). Cardiac troponin T was increased, and subepicardial inflammation and focal contractile dysfunction were detected by cardi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nguyen, Tien Dung, Mall, Gerhard, Westphal, Julian Georg, Weingärtner, Oliver, Möbius‐Winkler, Sven, Schulze, Paul Christian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8652969/ https://www.ncbi.nlm.nih.gov/pubmed/34536056 http://dx.doi.org/10.1002/ehf2.13613

Ejemplares similares

mRNA-1273: Myocarditis: case report
Publicado: (2021)

mrna-1273: Acute myocarditis: case report
Publicado: (2021)

Acute Myocarditis Following mRNA-1273 SARS-CoV-2 Vaccination
por: Williams, Curtis B., et al.
Publicado: (2021)

mrna-1273/tozinameran: Myocarditis: 8 case reports
Publicado: (2021)

Acute Myocarditis in a Patient Following mRNA-1273 SARS-CoV-2 Vaccination
por: Kawakami, Toshinaru, et al.
Publicado: (2022)

mRNA-1273/tozinameran: Myocarditis: 6 case reports
Publicado: (2021)

mRNA-1273/tozinameran: Myocarditis: 3 case reports
Publicado: (2021)

mRNA-1273/tozinameran: Myocarditis: 4 case reports
Publicado: (2022)

Myocarditis following COVID‐19 mRNA (mRNA‐1273) vaccination
por: Chellapandian, Suresh Babu, et al.
Publicado: (2022)

mRNA-1273/tozinameran: Acute myocarditis: 5 case reports
Publicado: (2022)

Case report: acute myocarditis following the second dose of mRNA-1273 SARS-CoV-2 vaccine
por: Tailor, Prashant D, et al.
Publicado: (2021)

Acute Myocarditis Following Vaccination With the First Dose of the mRNA-1273 Vaccine
por: Olagunju, Abdulbaril, et al.
Publicado: (2022)

Analysis of Myocarditis Among 252 Million mRNA-1273 Recipients Worldwide
por: Straus, Walter, et al.
Publicado: (2022)

Acute myocarditis after the third dose of COVID‐19 mRNA‐1273 vaccine
por: Yamada, Takayuki
Publicado: (2023)

2391. Evaluation and Adjudication of Case Reports of Myocarditis After mRNA-1273 Vaccination
por: Urdaneta, Veronica, et al.
Publicado: (2023)

Case report: SARS-CoV-2 specific T-cells are associated with myocarditis after COVID-19 vaccination with mRNA-1273
por: Stervbo, Ulrik, et al.
Publicado: (2023)

A 17-year-old male with acute myocarditis following mRNA-1273 vaccination in Japan
por: Iwamuro, Ayumi, et al.
Publicado: (2022)

Myocarditis After the Third Dose of mRNA-1273 Coronavirus Disease 2019 (COVID-19) Vaccine
por: Kawahara, Hiroshi, et al.
Publicado: (2022)

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
por: Baden, Lindsey R., et al.
Publicado: (2020)

Evaluation of mRNA-1273 SARS-CoV-2 Vaccine in Adolescents
por: Ali, Kashif, et al.
Publicado: (2021)

Risk of myocarditis and pericarditis following BNT162b2 and mRNA-1273 COVID-19 vaccination
por: Goddard, Kristin, et al.
Publicado: (2022)

Severe Myocarditis in a Female Following mRNA-1273 Vaccine: A Case Report and Review of the Literature
por: AL-Qudah, Bara M, et al.
Publicado: (2022)

Neutralization of SARS-CoV-2 Omicron BA.1, BA.4, and BA.5 by primary ChAdOx1 nCoV-19, mRNA-1273, MVC-COV1901 and booster mRNA-1273 vaccination
por: Liu, Yuag-Meng, et al.
Publicado: (2022)

Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination
por: Widge, Alicia T., et al.
Publicado: (2020)

Immunogenicity of Sars-Cov-2 mRNA 1273 Vaccine in Patients with Lymphoid Malignancies
por: Dong, Ning, et al.
Publicado: (2021)

Booster of mRNA-1273 Strengthens SARS-CoV-2 Omicron Neutralization
por: Doria-Rose, Nicole A., et al.
Publicado: (2021)

Diagnostics of messenger ribonucleic acid (mRNA) severe acute respiratory syndrome-corona virus‑2 (SARS-CoV‑2) vaccination-associated myocarditis—A systematic review
por: Federspiel, Jan M., et al.
Publicado: (2022)

Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
por: Anderson, Evan J., et al.
Publicado: (2020)

Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates
por: Corbett, Kizzmekia S., et al.
Publicado: (2020)

A short discussion about the SARS-CoV-2 mRNA-1273 vaccine
por: Oronsky, Bryan, et al.
Publicado: (2021)

Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase
por: El Sahly, Hana M., et al.
Publicado: (2021)

Serum Neutralizing Activity of mRNA-1273 against SARS-CoV-2 Variants
por: Choi, Angela, et al.
Publicado: (2021)

Durability of mRNA-1273-induced antibodies against SARS-CoV-2 variants
por: Pegu, Amarendra, et al.
Publicado: (2021)

Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants
por: Tseng, Hung Fu, et al.
Publicado: (2022)

Eosinophilic Granulomatosis with Polyangiitis after mRNA-1273 SARS-CoV-2 Vaccine
por: Mencarelli, Lucrezia, et al.
Publicado: (2023)

Tracking B cell responses to the SARS-CoV-2 mRNA-1273 vaccine
por: Lopes de Assis, Felipe, et al.
Publicado: (2023)

Myocarditis after BNT162b2 and mRNA-1273 COVID-19 vaccination: A report of 7 cases
por: Ahmed, Sirwan Khalid
Publicado: (2022)

Simultaneous Occurrence of Immune-Mediated Thrombocytopenia and Myocarditis After mRNA-1273 COVID-19 Vaccination: A Case Report
por: Bae, Dae-Hwan, et al.
Publicado: (2022)

Comparative Risk of Myocarditis/Pericarditis Following Second Doses of BNT162b2 and mRNA-1273 Coronavirus Vaccines
por: Naveed, Zaeema, et al.
Publicado: (2022)

Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants
por: Pegu, Amarendra, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_gtrh6kl7fac043svn52tegnl2l